News

Pharma companies have been eying digital health with interest, and the first quarter of 2018 was no exception.

Through a mix of studies, pilots, and deployments, the first quarter of 2018 saw a lot of providers moving deeper into digital health.

Cambridge, Massachusetts-based Common Sensing, which specializes in connected containers for injectable medications, has raised $6.

Brisbane, Australia-based ResApp Health, a digital health company that specializes in diagnosing respiratory diseases, is now conducting clinical proof-of-concept studies for its latest technology that uses a smartphone to detects sleep apnea by sound.

Lending an ear.

Personal genomics company Helix announced two new partnerships this week, both of which take the company — which has focused on ancestry and lifestyle applications in the past — strongly into the clinical realm.

Dr Robert Wachter, Professor and Chair of the Department of Medicine at the University of California, San Francisco, will be speaking at the HIMSS Europe & Health 2.0 conference in May in Sitges, Spain, supported by the Dutch Ministry of Health.

When stress levels are high, turning to an app for guided meditation might not be all that effective, according to a recent small study published in BMC Psychology.

The FDA has granted diagnostics company IDx’s De Novo request to market its AI-based software system for the autonomous detection of diabetic retinopathy in adults who have diabetes, called IDx-DR.

ActiGraph activity monitors and a mobile app from Clinical Ink are are at the heart of a newly announced pilot study backed by Bayer, according to a statement released today by ActiGraph.